Bicycle Therapeutics posted a net loss of $121.6 million for the nine months ended September 30, 2026. In March 2026 it announced a strategic reprioritization and a workforce reduction of approximately 30%, expected to reduce annual operating expenses by approximately 50%. It held $469.9 million in cash and cash equivalents as of September 30, 2026, which it believes funds operations for at least 12 months.
BCYC · Bicycle Therapeutics PLC
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Bicycle Therapeutics reported that nuzefatide pevedotin was granted FDA Orphan Drug Designation for pancreatic cancer in September 2026. Cash and cash equivalents were $469.9 million as of September 30, 2026, with expected cash runway into 2030.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCYC
this stock
Bicycle Therapeutics PLC
|
$213.79M | -56.9% | +105.8% | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 17
Bicycle Therapeutics posted a net loss of $121.6 million for the nine months ended September 30, 2026. In March 2026 it announced a strategic reprioritization and a workforce reduction of approximately 30%, expected to reduce annual operating expenses by approximately 50%. It held $469.9 million in cash and cash equivalents as of September 30, 2026, which it believes funds operations for at least 12 months.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCYC | -11.6% | -16.2% | -32.7% | -16.7% | -56.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -6.1% | -9.9% | -27.0% | -11.4% | -61.9% |